Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient satisfaction with self-administered teriparatide regimens in primary osteoporosis
jRCTs031210187Completed
- Sponsor
- Asahi Kasei Corporation
- Start
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of teriparatide in involutional osteoporosis (2 arms), sponsored by Asahi Kasei Corporation. Primary endpoint: Patient satisfaction rate at 26 weeks. Started Aug 2021; status: completed.
02
Drugs
teriparatide
03
Conditions
involutional osteoporosis
Beyond the preview
Go deeper on jRCTs031210187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210187.